Inclusion Criteria:  With age range of 18-65 years. BMI ≥ 28kg/m2 Fatty infiltration of the liver was confirmed on imaging studies (ultrasound, transient elastography, computed tomography, or magnetic resonance imaging) or liver biopsy. With valid motivational stage assessment based on TTM. Written consent form obtained.  Exclusion Criteria:  History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and Inherited metabolic liver diseases) and hemochromatosis. Self-reported HIV-positive status, active tuberculosis, active malaria, or inflammatory bowel disease. Excessive alcohol consumption (>30g/d for men and >20g/d for women). Patient has known cirrhosis (compensated/decompensated) either based on clinical criteria or liver histology or Imaging techniques. Subjects using thyroid hormones, oestrogens, amiodarone, steroids, tamoxifen and other medicine known to affect liver fat accumulation. Subjects using thiazolidinedione hypoglycemic drugs, vitamin E and other medicine have potential benefits for NASH within six months. Subjects with organ failure. Subjects with hepatocellular carcinoma or other active malignancy. Solid organ transplant recipients. Antibiotic treatment within the previous 3 months. Suffering from any acute or chronic cardiovascular, GI or immunological condition. Gastric or duodenal ulcer in the past six months. Currently pregnant or nursing. Concomitant diseases with reduced life expectancy. Combined mental illness. Contraindication to MRI scanning. Exclusions may also be made at the discretion of the attending physician or the eligibility committee. Inability to provide informed consent.